Pricing
  1. JP-listed companies
  2. TAKARA BIO INC.
  3. Financials
  4. EBITDA

TAKARA BIO INC.【JP:4974】

Market cap
¥138.1B
P/E ratio
-15.3x
Takara Bio develops and manufactures biotechnology products including research reagents, PCR instruments, and gene therapy treatments for universities, research institutions, and companies worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndEBITDA (Million JPY)YoY (%)
Mar 31, 20255,874-19.34%
Mar 31, 20247,282-70.39%
Mar 31, 202324,591-24.23%
Mar 31, 202232,456+89.01%
Mar 31, 202117,172+86.75%
Mar 31, 20209,195+12.77%
Mar 31, 20198,154+33.17%
Mar 31, 20186,123+24.35%
Mar 31, 20174,924+13.09%
Mar 31, 20164,354+19.32%
Mar 31, 20153,649

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)